Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chattem’s Dexatrim Looks For Cost-Conscious Consumers Unfriendly To Alli

This article was originally published in The Tan Sheet

Executive Summary

Chattem has not delivered a counter-punch to GlaxoSmithKline's alli, but the firm sees its Dexatrim supplement as "the only one left standing" to compete in the nonprescription weight-loss product category

You may also be interested in...

Petition Requests Pre-Market Approval For Supplement Weight-Loss Claims

Manufacturers would need pre-market approval to make weight-loss claims for supplements if FDA implements a rulemaking recommended by petitioners, including GlaxoSmithKline, the manufacturer of OTC weight-loss drug alli.

Chattem Posts Strong Q1 On Selsun Blue Naturals, ACT, Cortisone

The success of Selsun Blue Naturals is leading a revival of the Selsun dandruff franchise, fueling its strongest performance in six periods, Chattem said during an April 8 first quarter analyst call

Chattem Sales Up 51% Behind Ongoing Push From J&J Acquisitions

Brands Chattem acquired from Johnson & Johnson and continued growth of its own Gold Bond and Icy Hot drove a 51 percent increase in third-quarter revenues, the firm reported Sept. 27

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts